Effects of buprenorphine/naloxone in opioid-dependent humans

K. B. Stoller, G. E. Bigelow, S. L. Walsh, E. C. Strain

Research output: Contribution to journalArticlepeer-review

149 Scopus citations

Abstract

Rationale: Buprenorphine is a partial mu opioid agonist under development as a sublingual (SL) medication for opioid dependence treatment in the United States. Because buprenorphine may be abused, tablets combining buprenorphine with naloxone in a 4:1 ratio have been developed to reduce that risk. Low doses of injected buprenorphine/naloxone have been tested in opioid-dependent subjects, but higher doses (more than 2 mg of either medication) and direct comparisons to SL buprenorphine/naloxone have not been examined. Objectives: To assess and compare the effects of intramuscular (IM) versus SL buprenorphine/naloxone in opioid-dependent volunteers. Methods: Opioid-dependent volunteers were maintained on 40 mg per day of oral hydromorphone while on a residential research ward. After safety testing in two pilot subjects, participants (n=8) were tested with both IM and SL buprenorphine/naloxone (1/0.25, 2/0.5, 4/1, 8/2, 16/4 mg); IM hydromorphone (10 mg) and naloxone (0.25 mg); both IM and SL buprenorphine alone (8 mg); and placebo. Test sessions were twice per week; dosing was double-blind. Results: Intramuscular buprenorphine/naloxone produced dose-related increases on indices of opioid antagonist effects. Effects were consistent with naloxone-precipitated withdrawal, and were short-lived. As withdrawal effects dissipated, euphoric opioid agonist effects from buprenorphine did not appear. Sublingual buprenorphine/naloxone produced neither opioid agonist nor antagonist effects. Conclusions: Intramuscular injection of buprenorphine/naloxone precipitates withdrawal in opioid dependent persons; therefore, the combination has a low abuse potential by the injection route in this population. Sublingual buprenorphine/naloxone by tablet is well tolerated in opioid dependent subjects, and shows neither adverse effects (i.e., precipitated withdrawal) nor a high abuse potential (i.e., opioid agonist effects).

Original languageEnglish
Pages (from-to)230-242
Number of pages13
JournalPsychopharmacology
Volume154
Issue number3
DOIs
StatePublished - 2001

Keywords

  • Agonist-antagonist
  • Buprenorphine
  • Buprenorphine/naloxone
  • Hydromorphone
  • Naloxone
  • Opioid
  • Opioid dependence

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Effects of buprenorphine/naloxone in opioid-dependent humans'. Together they form a unique fingerprint.

Cite this